Dipiaron LLC
Dipiaron LLC is an innovative biotech start-up company, a participant of the Skolkovo project
Our project is aimed at creating a new original drug for the treatment of type 2 diabetes mellitus, metabolic syndrome and obesity.
The drug production technology has been developed, preclinical trials have been successfully carried out.
Thanks to venture investment from the PharmMed Innovations fund managed by Unicorn Capital Partners LLC, we have begun the next stage of project development - clinical trials
Our principles
Evidence
New milestones based on compelling evidence
Quality
Compliance with current research requirements at every stage of development and production
Further development
Exploring opportunities for expanding applications and new combinations
Team
Olga Golub
CEO
Ivan Tyurenkov
Director of Science
Daniil Nemenov
Clinical development consultant
Partners
ChemRar Group of Companies
Our site uses cookies, by staying on the page you agree to their use
Okay
Olga Golub
Since 2008 Olga has been working in the field of drug development. She has experience in managment of all stages of development of biotech start-up projects: raising funds, development and scaling up of manufacturing technology, conducting preclinical studies (in vitro and in vivo), obtaining permission for clinical trials, clinical trials, attracting a strategic partner for the later stages of project development.
Previously developed products have successfully passed all stages of development and are at the stage of state registration procedure and commercialization.
In 2005 Olga graduated from the Department of Analytical and Medical Biochemistry and Microbiology of Voronezh State University. She has a master's degree in biology (specialization in biochemistry). Then she studied as postgraduate student at the A.N. Bach Institute of Biochemistry (Russian Academy of Sciences).
Previously developed products have successfully passed all stages of development and are at the stage of state registration procedure and commercialization.
In 2005 Olga graduated from the Department of Analytical and Medical Biochemistry and Microbiology of Voronezh State University. She has a master's degree in biology (specialization in biochemistry). Then she studied as postgraduate student at the A.N. Bach Institute of Biochemistry (Russian Academy of Sciences).
Ivan Tyurenkov
Head of the Department of Experimental Pharmacology and Toxicology of the Scientific Center for Innovative Medicines with Pilot Production, Head of the Laboratory of Pharmacology of Cardiovascular Drugs of the Scientific Center for Innovative Medicines with Pilot Production, Head of the Department of Pharmacology and Pharmacy of the Institute of Continuing Medical and Pharmaceutical Education of the Volgograd State Medical University of the Ministry of Health of the Russian Federation. Corresponding member of the Russian Academy of Sciences, Honored Scientist of the Russian Federation, Doctor of Medicine, Professor.
Ivan has extensive experience in the field of preclinical research and drug development, including the search and development of innovative molecules, investigation of mechanisms of action, and the conduct of preclinical studies.
He was directly involved in the development and introduction into clinical practice of the drug "Phenotropil". Under his scientific guidance, 4 state contracts for the development of original domestic medicines were completed.
Ivan published over 1000 scientific articles, received more than 100 patents for inventions and copyright certificates.
Ivan has extensive experience in the field of preclinical research and drug development, including the search and development of innovative molecules, investigation of mechanisms of action, and the conduct of preclinical studies.
He was directly involved in the development and introduction into clinical practice of the drug "Phenotropil". Under his scientific guidance, 4 state contracts for the development of original domestic medicines were completed.
Ivan published over 1000 scientific articles, received more than 100 patents for inventions and copyright certificates.
Daniil Nemenov
Daniil has extensive experience in planning and managing the processes of all phases of clinical trials of innovative and generic/biosimilar pharmaceuticals (biological and chemical molecules): CRO selection, contracting, supervision and communication to ensure timely and smooth achievement of milestones, analysis of results; as well as communication with Russian, the US and German regulatory authorities.
In addition, Daniil has experience in general management of biotechnology companies: from lead drug candidate to regulatory approval and licensing deals, market access on Russian and international market.
Medicines developed under Daniel's leadership are at the stage of state registration procedure and commercialization.
In 2005, Daniel graduated from the Sechenov Moscow Medical Academy (“General Medicine”), then underwent residency at the Moscow Institute of medico-social rehabilitation the Department of nervous diseases (specialty “Neurology”)
In addition, Daniil has experience in general management of biotechnology companies: from lead drug candidate to regulatory approval and licensing deals, market access on Russian and international market.
Medicines developed under Daniel's leadership are at the stage of state registration procedure and commercialization.
In 2005, Daniel graduated from the Sechenov Moscow Medical Academy (“General Medicine”), then underwent residency at the Moscow Institute of medico-social rehabilitation the Department of nervous diseases (specialty “Neurology”)